Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medicamen OrganicsNSE:MEDIORG -4.86%21 PS Ratio is 6.99 as of Aug. 06, 2026, which is 478% above its 10-year median of 1.21. GuruFocus rates NSE:MEDIORG with a GF Score™ of 21/100. The stock has 11 warning signs investors should review. Among 953 Drug Manufacturers companies, Medicamen Organics ranks worse than 78.17% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Medicamen Organics's share price is ₹28.40.
Medicamen Organics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹4.06. Hence, Medicamen Organics's PS Ratio for today is 6.99.
The historical rank and industry rank for Medicamen Organics's PS Ratio or its related term are showing as below:
NSE:MEDIORG'
s PS Ratio Range Over the Past 10 Years
Min: 0.61 Med: 1.21 Max: 6.7
Current: 6.06
During the past 6 years, Medicamen Organics's highest PS Ratio was 6.70. The lowest was 0.61. And the median was 1.21.
NSE:MEDIORG's PS Ratio is ranked worse than 78.17% of 953
companies
in the Drug Manufacturers industry
Industry Median: 2.32
vs NSE:MEDIORG: 6.06
Medicamen Organics Ltd revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Medicamen Organics was -44.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 0.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 4.50% per year.
During the past 6 years, Medicamen Organics's highest 3-Year average Revenue per Share Growth Rate was 24.40% per year. The lowest was 0.30% per year. And the median was 0.50% per year.
Medicamen Organics (NSE:MEDIORG) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Medicamen Organics PS Ratio Related Terms
Medicamen Organics PS Ratio Historical Data
* Premium members only.
The historical data trend for Medicamen Organics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medicamen Organics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicamen Organics PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medicamen Organics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Medicamen Organics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Medicamen Organics's Share Price of today is ₹28.40.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medicamen Organics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹4.06.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Medicamen Organics (NSE:MEDIORG) has a PS Ratio of 6.99 as of Aug. 06, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Medicamen Organics and its competitors. This is 478% above median its historical median of 1.21. Over the past decade, Medicamen Organics' PS Ratio has ranged from 0.61 to 6.70. According to the industry distribution chart, Medicamen Organics ranks #745 out of 953 companies in the Drug Manufacturers industry, placing it in the top 78.2%.
Is Medicamen Organics' PS Ratio too high?
Medicamen Organics' current PS Ratio of 6.99 is 478% above median its 10-year median of 1.21. Over the past 10 years, this metric has ranged from a low of 0.61 to a high of 6.70. The Drug Manufacturers industry median PS Ratio is 2.32. Medicamen Organics' value of 6.99 is 201.3% above this industry median. Based on the distribution chart, Medicamen Organics ranks #745 out of 953 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Medicamen Organics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Medicamen Organics' PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Medicamen Organics ranks #745 out of 953 companies for PS Ratio. This places Medicamen Organics in the lower half of its industry. The industry median PS Ratio is 2.32. Medicamen Organics' value of 6.99 is 201.3% above this benchmark. Historically, Medicamen Organics' own PS Ratio has ranged from 0.61 to 6.70 over the past decade. While the company's 10-year median is 1.21 vs. the industry median of 2.32, Medicamen Organics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.32, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medicamen Organics's current PS Ratio of 6.99 is 201.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Medicamen Organics and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicamen Organics's current PS Ratio is 6.99, which is 478% above median its own 10-year median of 1.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicamen Organics stock overvalued right now?
Medicamen Organics (NSE:MEDIORG) has a current PS Ratio of 6.99. The current PS Ratio is 6.99, which is 478% above median its 10-year median of 1.21 and 201.3% above the Drug Manufacturers industry median of 2.32. Medicamen Organics' overall GF Score™ is 21/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Medicamen Organics (NSE:MEDIORG), the current PS Ratio is 6.99 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medicamen Organics Ltd develops, manufactures, and distributes a wide range of pharmaceutical dosage forms, including Tablets, Capsules, Oral Liquids, Ointments, Gel, Syrups, Suspension and Dry powders. The company operates two WHO Good Manufacturing Practice certified facilities in India, producing products for both domestic and international clients. It provides contract manufacturing and loan license services to various pharmaceutical companies and exports to several countries across Africa, CIS, and South Asia. The principal source of revenue is through the manufacturing, export, and contract services focused on generic and branded pharmaceutical formulations.
21GF Score
Get the complete analysis for NSE:MEDIORG
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MEDIORG has been successfully added to your 
